.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
Farmers Insurance
Cerilliant
Merck
Colorcon
Harvard Business School
Novartis
Cipla
Accenture
Teva

Generated: September 22, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title:Substituted thiazolidinedione derivatives
Abstract: A compound of formula (I): ##STR00001## .Iadd.or a tautomeric form thereof, .Iaddend.wherein: R.sup.1 represents a hydrogen atom, C.sub.1-12 alkyl, C.sub.1-12 alkoxy, C.sub.1-12 alkylcarbonyl or arylC.sub.1-12 alkyl; A.sup.1 represents hydrogen or 1 to 4 optional substituents selected from the group consisting of: C.sub.1-12 alkyl, C.sub.1-12 alkoxy, aryl, and halogen; aryl represents phenyl or naphthyl optionally substituted with up to five groups selected from halogen, C.sub.1-12 alkyl, phenyl, C.sub.1-12 alkoxy, haloC.sub.1-12 alkyl, hydroxy, nitro, C.sub.1-12 alkoxycarbonyl, C.sub.1-12 alkoxycarbonyl C.sub.1-12 alkyl, C.sub.1-12 alkoxycarbonyloxy, or C.sub.1-12 alkylcarbonyl: A.sup.2 represents a benzene ring having 1 to 3 optional substituents selected from hydrogen, halogen, C.sub.1-12 alkyl, C.sub.1-12 alkoxy; and M.sup.- represents a counter-ion other than the maleate ion.
Inventor(s): Buxton; Philip Christopher (Harlow, GB), Mackenzie; Donald Colin (St. Albans, GB)
Assignee: SmithKline Beecham p.l.c. (GB)
Filing Date:Mar 17, 2003
Application Number:10/389,381
Claims:1. A compound .[.of formula (I): ##STR00007## or a tautomeric form thereof, wherein: R.sup.1 represents a hydrogen atom, C.sub.1-12 alkyl, C.sub.1-12 alkoxy, C.sub.1-12 alkylcarbonyl or arylC.sub.1-12 alkyl; A.sup.1 represents hydrogen or 1 to 4 optional substituents selected from the group consisting of: C.sub.1-12 alkyl, C.sub.1-12 alkoxy, aryl and halogen; aryl represents phenyl or naphthyl optionally substituted with up to five groups selected from halogen, C.sub.1-12 alkyl, phenyl, C.sub.1-12 alkoxy, haloC.sub.1-12 alkyl, hydroxy, nitro, C.sub.1-12 alkoxycarbonyl, C.sub.1-12 alkoxycarbonyl, C.sub.1-12 alkoxycarbonyloxy, or C.sub.1-12 alkylcarbonyl; A.sup.2 represents a benzene ring having 1 to 3 optional substituents selected from hydrogen, halogen, C.sub.1-12 alkyl, C.sub.1-12 alkoxy; and M.sup.- represents a counter-ion other than the maleate ion.]. .Iadd.which is 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione tartaric acid salt or a tautomer of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione tartaric acid salt..Iaddend.

2. A process for the preparation of a compound .[.of formula (I).]. according to claim 1.[., or a tautomeric form thereof,.]. which process comprises reacting .[.a compound of formula (II): ##STR00008## wherein R.sup.1, A.sup.1, and A.sup.2 are as defined in relation to formula (I) in claim 1, with a source of counter-ion M.sup.- which is defined in relation to formula (I), as defined in claim 1.]. .Iadd.5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4- -dione or a tautomeric form thereof with a source of tartarate ion..Iaddend.

.Iadd.3. The compound according to claim 1, wherein the salt is in a solid form..Iaddend.

.Iadd.4. A pharmaceutical composition comprising a compound according to claim 1 and at least one pharmaceutically acceptable carrier..Iaddend.

.Iadd.5. The pharmaceutical composition according to claim 4 comprising an individual isomer of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione tartaric acid salt or a tautomer of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione tartaric acid salt..Iaddend.

.Iadd.6. The pharmaceutical composition according to claim 4 comprising a mixture of isomers of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]hiazolidine-2,4-dione tartaric acid salt or a tautomer of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione tartaric acid salt..Iaddend.

.Iadd.7. The pharmaceutical composition according to any one of claims 4 to 6, wherein the composition is in a form suitable for oral administration..Iaddend.

.Iadd.8. The pharmaceutical composition according to claim 7, wherein the form is chosen from tablets, capsules, and powders..Iaddend.

.Iadd.9. The pharmaceutical composition according to claim 7, wherein the form is a tablet..Iaddend.

.Iadd.10. The pharmaceutical composition according to claim 4, wherein the composition is in a form suitable for injection..Iaddend.

.Iadd.11. The pharmaceutical composition according to claim 4, wherein the composition is in a form suitable for percutaneous absorption..Iaddend.

.Iadd.12. The pharmaceutical composition according to claim 4, wherein the at least one pharmaceutically acceptable carrier is chosen from microcrystalline cellulose, starch, sodium starch glycollate, polyvinylpyrrolidone, polyvinylpolypyrrolidone, magnesium stearate, and sodium lauryl sulphate..Iaddend.

.Iadd.13. The pharmaceutical composition according to claim 4, wherein the at least one pharmaceutically acceptable carrier comprises a diluent, filler, disintegrant, wetting agent, lubricant, colourant, flavourant, or adjuvant..Iaddend.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
Dow
Express Scripts
Teva
Julphar
US Army
Argus Health
UBS
Cipla
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot